The beneficial effects of renin–angiotensin system inhibitors (RASI) on IgA nephropathy with tubulointerstitial lesions categorized by Oxford classification

Kamiyama, Takahiro; Moriyama, Takahito; Kumon, Saeko; Karasawa, Kazunori; Nitta, Kosaku

doi:10.1007/s10157-019-01713-w

Cited by 6 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The application of RAS inhibitors has shown a significant beneficial effect on patients with histologically advanced IgAN with tubuleinterstitial lesions. Multivariate Cox regression analysis showed that the RAS inhibitor was an independent factor in slowing down disease progression 174 . Aliskiren is the first in a class of drugs called direct renin inhibitors and has been demonstrated to reduce the mean ratio of urinary protein-to-creatinine, the activity of renin in plasma, and the level of IL-6 or transforming growth factor-β in patients with IgAN 175 .…”

Section: Therapeutic Strategies With An Updated Pathophysiological Pementioning

confidence: 99%

Perspectives on how mucosal immune responses, infections and gut microbiome shape IgA nephropathy and future therapies

He¹,

Zhou²,

Lv³

et al. 2020

Theranostics

View full text Add to dashboard Cite

Infections have been considered to play a critical role in the pathogenesis of IgA nephropathy (IgAN) because synpharyngitic hematuria is a common feature in IgAN. However, how infections participate in this process is still debated. More recent studies have also revealed that the alteration of the gut microbiome exerts a profound effect on host immune responses, contributing to the etiology or progression of autoimmunity. Considering IgA as the first line of defense against bacterial and viral antigens, this review evaluates the relationships among intestinal infections, gut microbiome, and IgA for a better understanding of the pathogenesis of IgAN. Moreover, as a prototype of IgA immunity, we provide detailed clarification of IgAN pathogenesis to shed light on other diseases in which IgA plays a role. Finally, we discuss potential therapies focusing on microbes and mucosal immune responses in IgAN.

show abstract

Section: Therapeutic Strategies With An Updated Pathophysiological Pementioning

confidence: 99%

Perspectives on how mucosal immune responses, infections and gut microbiome shape IgA nephropathy and future therapies

He¹,

Zhou²,

Lv³

et al. 2020

Theranostics

View full text Add to dashboard Cite

show abstract

The impact of tonsillectomy combined with steroid pulse therapy in patients with advanced IgA nephropathy and impaired renal function

et al. 2019

View full text Add to dashboard Cite

Evaluation of appropriate treatment for IgA nephropathy with mild proteinuria and normal renal function

et al. 2021

View full text Add to dashboard Cite

The beneficial effects of renin–angiotensin system inhibitors (RASI) on IgA nephropathy with tubulointerstitial lesions categorized by Oxford classification

Cited by 6 publications

References 32 publications

Perspectives on how mucosal immune responses, infections and gut microbiome shape IgA nephropathy and future therapies

Perspectives on how mucosal immune responses, infections and gut microbiome shape IgA nephropathy and future therapies

The impact of tonsillectomy combined with steroid pulse therapy in patients with advanced IgA nephropathy and impaired renal function

Evaluation of appropriate treatment for IgA nephropathy with mild proteinuria and normal renal function

Contact Info

Product

Resources

About